Walter Public Investments Inc. Sells 59,083 Shares of Cellebrite DI Ltd. $CLBT

Walter Public Investments Inc. lessened its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 11.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 453,532 shares of the company’s stock after selling 59,083 shares during the quarter. Walter Public Investments Inc.’s holdings in Cellebrite DI were worth $6,250,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its position in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Cellebrite DI during the 3rd quarter worth approximately $40,000. CWM LLC increased its holdings in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares during the last quarter. First Horizon Corp raised its stake in Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after acquiring an additional 2,337 shares during the period. Finally, Vestcor Inc acquired a new stake in Cellebrite DI during the 3rd quarter valued at $70,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock opened at $15.65 on Friday. The company has a market cap of $3.90 billion, a PE ratio of 55.89, a price-to-earnings-growth ratio of 1.94 and a beta of 1.17. The company has a 50 day moving average of $13.40 and a 200-day moving average of $14.61. Cellebrite DI Ltd. has a 1-year low of $11.02 and a 1-year high of $19.98.

Insider Buying and Selling

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 13,269 shares of company stock worth $169,592 in the last three months. 5.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

CLBT has been the subject of several research reports. DA Davidson initiated coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective for the company. Needham & Company LLC cut their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.40.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.